Testing whether a gene variant affects response to Humira in psoriasis
Tests Humira in adults with psoriasis, looking at an IL 12B gene variant.
Key facts
- Who runs it
- South Valley University
- Where
- Qina, EgyptSee the site
- Trial code
- Registry title
- Evaluation of IL 12B Genetic Polymorphism (rs3213094)
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 1 Aug 2025
- Planned end
- 1 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Humira
- Record updated
- 19 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70 with severe psoriasis and psoriatic arthritis, treated with Humira, to study a gene change (IL 12B rs3213094) and the response to Humira.
- Age
- 18 to 70 years
- Sex
- Men and women can join.
- Disease stage
- Psoriasis diagnosed for at least 6 months, severe: PASI score greater than 10 and more than 10% of body surface area involved, together with psoriatic arthritis.
- Earlier treatment
- No treatment other than Humira, now or in the last 6 months.
- Biomarker or test result
- The trial looks at the IL 12B gene change (rs3213094).
Main reasons for not taking part
- Other autoimmune or inflammatory conditions (for example rheumatoid arthritis, lupus)
- Pregnancy and breastfeeding
- Known genetic disorders that affect the immune system
- Active infections, including tuberculosis, hepatitis B or C, HIV
- Renal and vascular diseases
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis
Who cannot take part
- Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus)
- Patients with known genetic disorders affect immune system function
- Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV)
- Renal \&Vascular diseases
- Pregnancy and lactation
- Patients currently undergoing any treatment other than Humira
- Patients were undergoing any treatment other than Humira in the last 6 months
- Patients with contraindication to Humira
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in Egypt
- Qina University hospital, South Valley University HospitalQina, EgyptContact: Ebtehal Alaa El-Din Kotop Mohamed, LecturerTaking people
About the trial
What the trial wants to find out
Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.
The 2 groups in the trial
- Patients GroupExisting treatment, for comparison
About 20 patients with psoriasis and psoriatic arthritis.
Treatment: Humira
- Healthy GroupExisting treatment, for comparison
About 20 healthy control group.
Treatment: Humira
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of IL 12B Genetic Polymorphism (rs3213094) in Patient With Psoriasis and Psoriatic Arthritis in Response to Humira
- Plain-language title
- Testing whether a gene variant affects response to Humira in psoriasisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07128472, who can take part
- Record updated
- 19 August 2025